These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12823076)

  • 21. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
    Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD; Sanger TM; Lu Y; Thieme ME
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J; Inada T; Miura S
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in clinical response to olanzapine compared with haloperidol.
    Goldstein JM; Cohen LS; Horton NJ; Lee H; Andersen S; Tohen M; Crawford A; Tollefson G
    Psychiatry Res; 2002 May; 110(1):27-37. PubMed ID: 12007591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees.
    Manuel JI; Essock SM; Wu Y; Pangilinan M; Stroup S
    Psychiatr Serv; 2012 Nov; 63(11):1146-9. PubMed ID: 23117514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
    Barak Y; Shamir E; Zemishlani H; Mirecki I; Toren P; Weizman R
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1199-202. PubMed ID: 12452546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
    Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
    Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
    Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
    Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
    Gothelf D; Apter A; Reidman J; Brand-Gothelf A; Bloch Y; Gal G; Kikinzon L; Tyano S; Weizman R; Ratzoni G
    J Neural Transm (Vienna); 2003 May; 110(5):545-60. PubMed ID: 12721815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
    Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
    Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
    Hamilton SH; Edgell ET; Revicki DA; Breier A
    Int Clin Psychopharmacol; 2000 Sep; 15(5):245-55. PubMed ID: 10993126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.